Complicated Urinary Tract Infection – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
A complicated urinary tract infection is a urinary infection that occurs in a patient who has a genitourinary tract structural or functional abnormality. Complicated urinary infections can be linked to a wide range of genitourinary abnormalities. Interference with normal voiding is the most common cause of disease, as it prevents bacteria from being flushed out of the genitourinary tract. Infection can be caused by incomplete urinary drainage, the persistence of bacteria in biofilm on stones or indwelling devices, or increased organism introduction into the genitourinary tract due to instrumentation. The risk of disease varies depending on the abnormality. A chronic indwelling catheter, for example, is always associated with bacteriuria, whereas disease caused by a single obstructing ureteric stone can be transient, especially when the stone is removed.
The prevalence of bacteriuria is very high,
reaching 100% in patients with chronic indwelling catheters, 30% to 40% in patients
with a neurogenic bladder managed by intermittent catheterization, and 50% in
elderly nursing homes residents.
The competitive
landscape of Complicated Urinary Tract Infection includes country-specific
approved and pipeline therapies. Any asset/product-specific designation or
review and Accelerated Approval are tracked and supplemented with analyst
commentary.
KOLs insights of Complicated
Urinary Tract Infection across the 8 MM market from the center of Excellence/
Public/ Private hospitals participated. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Complicated
Urinary Tract Infection Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 Cefepime-Taniborbactam Venatorx
Pharmaceuticals, Inc. Phase 3
2 Ceftazidime -avibactam Pfizer Phase 2
3 Cefepime-zidebactam Wockhardt Phase 3
4 Benapenem Sihuan
Pharmaceutical Holdings Group Ltd. Phase
3
5 Eravacycline La
Jolla Pharmaceutical Company Phase
3
6 CXA-201 Cubist
Pharmaceuticals LLC Phase 3
7 Tebipenem Pivoxil Hydrobromide Spero Therapeutics Phase
3
8 Meropenem- FL058 Qilu
Pharmaceutical Co., Ltd. Phase 2
9 Sulbactam-ETX2514 Entasis
Therapeutics Phase 2
10 Plazomicin Achaogen,
Inc. Phase 3
Continued
Comments
Post a Comment